Abiopharma

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

New Form SCHEDULE 13G - JOINT Corp Filed: 2026-01-08 AccNo: 0001821268-26-000003 Size: 6 KB

Curaleaf Announces Proposed Domestication to Delaware

(90% Positive) Context Therapeutics Inc. (CNTX) Provides Update on reflected for such are reasonable

New Form ARS - Modular Medical, Inc. Filed: 2026-01-08 AccNo: 0001213900-26-002333 Size: 731 KB

New Form DEF 14A - Modular Medical, Inc. Filed: 2026-01-08 AccNo: 0001213900-26-002332 Size: 22 MB

GH Research PLC (GHRS) Files Form 6-K

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference

Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology